Drug and Gene Delivery Devices Market (By Delivery Type: Oral, Ocular, Inhalation, Nasal, Injectable, Transdermal, and Topical; By Method: In Situ and Ex Vivo; By Vector: Viral and Non-Viral) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032

The drug and gene delivery devices market size was estimated at USD 460.9 billion in 2022 and is expected to surpass around USD 932.4 billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 7.3% during the forecast period 2023 to 2032.

Key Takeaways:

• Based on method, the in situ segment accounted largest revenue share in 2022 and is projected to remain its dominance during the forecast period.
• Based on vector, the viral vector segment accounted largest revenue share in 2022
• North America dominated the global drug and gene delivery devices market in 2022, in terms of revenue and is estimated to sustain its dominance during the forecast period.

Drug And Gene Delivery Devices Market Report Scope

Growing efforts towards formulating dosage forms that would help in maximizing the bioavailability of the drug at the target site while increasing patient convenience are driving the global market growth. The introduction of novel drug delivery systems such as subdermal implants that are available in different forms such as rings and patches are expected to aid in the industry growth.

The evolution of the drug delivery systems is directly attributed to changing preferences by patients as well as healthcare professionals. A few of the many advancements include

• Introduction of Biopharmaceutical classification systems (BCS) class II drug in oral dosage forms
• Introduction of auto-injectors
• Availability of advanced implants in customized shapes and sizes
• Introduction of advanced pulmonary devices such as Smartcard and Adaptive Aerosol Delivery

Drug And Gene Delivery Devices Market Trends

The global market for drug and gene delivery devices has expanded with the increased prevalence of numerous chronic diseases, such as cancer, diabetes, cardiovascular diseases, and other technological developments in drug delivery. Additionally, the demand for drug and gene delivery devices has grown with the patients' and physicians' changing preferences, driving the market's expansion.

The market for drug and gene delivery devices is anticipated to rise owing to the increasing need for injectable medications. The global market for drug and gene delivery devices has expanded with the increased prevalence of numerous chronic diseases like cancer, diabetes, cardiovascular diseases, and other technological developments in drug delivery. Additionally, the major players in the field of genomics are increasing their efforts in research and development. The demand for drug and gene delivery devices has grown with the patients' and physicians' changing preferences, driving the market's expansion.

The market for drug and gene delivery devices is anticipated to rise owing to the increasing need for injectable medications. Players in the injectable medicine market are getting regulatory approval for various treatments used in syringes to increase their market share over the forecast period.

The market for drug delivery devices is anticipated to hinder due to regulatory approvals uncertainties. Investments in new product innovations are pushed to the limit due to the possibility of revenue loss from delays in product releases and increased costs paid due to strict regulatory processes, which is impacting the expansion of the drug and gene delivery devices market.

Technological developments in injectable medical equipment have accelerated patient acceptance of self-injectable devices. Since the diabetic patient has to inject insulin regularly, the growing diabetic population is driving the expansion of this market. The rise in popularity of self-injectors, pen-injectors, needle-free injectors, and auto-injectors has made it possible for patients to administer medications at home without needing medical help. The drug and gene delivery device market is anticipated to be significantly impacted by all of these factors, which is expected to increase demand for injectable products over the forecast period.

Delivery Type Insights

Based on delivery type, the oral segment dominated the global drug and gene delivery devices market in 2022, in terms of revenue and is estimated to sustain its dominance during the forecast period. The oral drug delivery is the most convenient and most popular route of administration all over the globe. It is economical, pain-free, and self-administered type of delivery where no sterile precautions are involved. Moreover, the development of various therapeutics that can identify the affected cell and can treat that cell without harming the normal cells is exponentially boosting the growth of this segment. Therefore, the rapid growth of the biosimilar, targeted therapeutics, and gene therapies had positively impacted the market growth in the past few years.

On the other hand, the injectable is estimated to be the most opportunistic segment during the forecast period. The technological advancements in the injectable devices has propelled the adoption of the self-injectable devices among the patients. The rising number of diabetic population is fostering the growth of this segment as the diabetic patient need to regularly inject insulin. The increasing popularity of the self-injectors, needle-free injectors, pen-injectors, and auto-injectors has allowed the patients to conveniently administer drugs from the convenience of their home, eliminating the medical assistance. All these factors are estimated to have a significant impact on the drug and gene delivery devices market and will foster the demand for the injectable segment in the forthcoming years.

Methods Insights

Based on the method used, gene delivery system is segmented as in situ and ex vivo. Most of the currently approved drugs act by in situ methods. Thus, the in situ segment is currently dominating the industry with the largest share.

High focus on the in situ methods owing to its ease of performance is expected to make it the fastest growing segment in the space. However, the segment growth is expected to impede the low efficiency of transduction procedures.

Vector Insights

Viral vectors currently dominate the gene delivery systems market with 4 approved drugs. More than 80% of the ongoing clinical trials on gene therapies are based on the viral vectors for transfection. Thus, the viral segment is expected to remain dominant throughout the forecast period.

Viral vectors enable complex procedures involved in transfection procedures such as gene gun, magnetofection, ultrasound, and hydrodynamic. In addition, it has increased the success rate of the gene transfer as compared to its counterpart techniques

Regional Insights

North America captured the largest market share in 2022. The presence of a large number of key players and high adoption rate of the advanced methods are the factors driving the industry growth in the region. In addition, high investment in R&D by the U.S. government and industry participants is augmenting the industry growth of the region.

Asia Pacific is expected to show a lucrative growth rate during the forecast period owing to factors such as growing awareness about the novel systems as well as the influx of the international industry players to seek opportunities in the untapped market in the region.

Recent Development

• In June 2022, Roche announced the launch of its Human papillomavirus (HPV) self-sampling equipment. HPV screening assists in identifying women who are at risk of developing cervical cancer, allowing early diagnosis and treatment of the problem.
• Key players operating in the gene delivery systems include Uniqure N.V., SiBiono GeneTech Co., Epeius Biotechnologies Corporation, Shanghai Sunway Biotech Co., Ltd, and Human Stem Cells Institute. These companies are also engaged in the R&D of their products to explore further applications in different physiological conditions.

Some of the prominent players in the Drug And Gene Delivery Devices Market include:

• Pfizer, Inc.
• F. Hoffmann-La Roche Ltd
• Johnson and Johnson Private Ltd
• Novartis AG
• Bayer AG
• Becton, Dickinson and Company
• Uniqure NV

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the Drug And Gene Delivery Devices market.

By Delivery Type

• Oral
• Ocular
• Inhalation
• Nasal
• Injectable
• Transdermal
• Topical

By Method

• In Situ
• Ex Vivo

By Vector

• Viral Vector
• Non-Viral Vector

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)